论文部分内容阅读
目的观察紫杉醇联合顺铂方案(TP方案)治疗晚期非小细胞肺癌(NSCLC)的临床疗效和毒副作用。方法63例中晚期NSCLC患者均采用TP方案化疗,观察有效率、中位生存期、1年生存率及毒副作用。结果63例患者总有效率为49.2%(31/63),初治组和复治组的有效率分别为57.1%(24/42)和33.3%(7/21),两组比较差异无统计学意义(χ2=3.7154,P=0.0748),中位生存期(12.00±0.64)月,1年生存率为31.1%;常见的毒副作用为骨髓抑制及消化道反应,但均在可耐受的范围内。结论TP方案治疗晚期非小细胞肺癌能取得较好的疗效,患者耐受性较好。
Objective To observe the clinical efficacy and side effects of paclitaxel combined with cisplatin (TP) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Sixty - three patients with advanced non - small cell lung cancer (NSCLC) were treated with TP regimen. The effective rate, median survival time, 1 year survival rate and side effects were observed. Results The total effective rate of 63 patients was 49.2% (31/63). The effective rates of the two groups were 57.1% (24/42) and 33.3% (7/21) respectively, there was no statistical difference between the two groups (Χ2 = 3.7154, P = 0.0748). The median survival time was (12.00 ± 0.64) months and the 1-year survival rate was 31.1%. Common toxicities and side effects were myelosuppression and gastrointestinal reactions, but all were tolerable Range. Conclusion TP regimen in the treatment of advanced non-small cell lung cancer can achieve better efficacy, patients with better tolerance.